Orchid Pharma Limited – Investor Presentation Summary

Key Operational Highlights

  • Built on 30 years of cephalosporin expertise.
  • Company is India's only USFDA-approved sterile cephalosporin manufacturer.
  • Shifting sterile capacity to regulated markets to directly improve margin quality.
  • Plans to launch 5-6 sterile products in the US by 2030.
  • Key drivers include API self-supply providing a structural cost edge vs pure-play FDF competitors.

Segment-wise Performance

Not Specified

Financial Highlights

Q4 FY26 (Standalone) Performance:

  • Revenue from Operations: ₹238 Cr (vs ₹237 Cr in Q4-25, +0% YoY)
  • Other Income: ₹13 Cr (vs ₹6 Cr in Q4-25, +117% YoY)
  • COGS: ₹151 Cr (vs ₹138 Cr in Q4-25)
  • Employee Expense: ₹20 Cr (vs ₹22 Cr in Q4-25, -9% YoY)
  • Other Expense: ₹38 Cr (vs ₹43 Cr in Q4-25, -12% YoY)
  • EBITDA: ₹42 Cr (vs ₹40 Cr in Q4-25, +5% YoY)
  • EBITDA Margin: 18% (vs 17% in Q4-25)
  • Interest: ₹3 Cr (vs ₹4 Cr in Q4-25, -25% YoY)
  • Depreciation: ₹9 Cr (vs ₹9 Cr in Q4-25)
  • Exceptional Items: ₹1 Cr (vs ₹0 Cr in Q4-25)
  • PAT: ₹30 Cr (vs ₹28 Cr in Q4-25)

Full Year FY26 (Standalone) Performance:

  • Revenue from Operations: ₹811 Cr (vs ₹922 Cr in FY25, -12% YoY)
  • Other Income: ₹55 Cr (vs ₹32 Cr in FY25, +72% YoY)
  • COGS: ₹526 Cr (vs ₹544 Cr in FY25)
  • Employee Expense: ₹88 Cr (vs ₹86 Cr in FY25, +2% YoY)
  • Other Expense: ₹152 Cr (vs ₹168 Cr in FY25, -10% YoY)
  • EBITDA: ₹101 Cr (vs ₹156 Cr in FY25, -36% YoY)
  • EBITDA Margin: 12% (vs 17% in FY25)
  • Interest: ₹13 Cr (vs ₹15 Cr in FY25, -13% YoY)
  • Depreciation: ₹36 Cr (vs ₹35 Cr in FY25)
  • Exceptional Items: -₹6 Cr (vs ₹0 Cr in FY25)
  • PAT: ₹45 Cr (vs ₹106 Cr in FY25)

Drivers of financial performance: Not explicitly specified beyond operational highlights.

Comparison to market estimates: Not provided.

Key Risks: Not disclosed in the presentation.

Geographical Revenue Split

Not Specified

Balance Sheet Snapshot

Not Specified

Capex & Cash Flow Health

  • Capital Expenditure: ₹750 Cr committed for 7-ACA + Downstream Integration (1,000 MT capacity, 750 MT captive)
  • Project investment of $20-25 Mn (approximately ₹200 Cr) committed for Cefiderocol project (1 Mn vial capacity)
  • Investment Rationale: 7-ACA integration eliminates China dependence and improves overall margin; Cefiderocol project opens emerging market opportunities.

Strategic & R&D Initiatives

Investments in Innovation:

  • EXBLIFEP - India's only novel antibiotic platform creating a scalable royalty income stream
  • Cefiderocol - Next-generation siderophore cephalosporin active against resistant gram-negative bacteria
  • FDF Capability & Filings targeting 5-6 sterile US launches by 2030 (Ceftaroline, Ceftazidime-Avibactam, Ceftolozane)
  • Peptide research and new dossier filings

Expected impact on growth:

  • API self-supply gives Orchid a structural cost edge vs pure-play FDF competitors
  • Each FDF unit captures more margin than API alone
  • Cefiderocol extends Orchid's range into the most resistant cases and reinforces AMR credibility

Strategic Rationale:

  • Expanding into high-growth markets through regulated market focus
  • Reducing operational costs through backward integration into 7-ACA
  • Positioning as an anti-infective innovator, not just an API manufacturer

Industry Trends & Business Environment

Macro/Industry Trends:

  • Global cUTI Burden: 8,560 patients per 1,000 population (varying 0.4-1.0 globally)
  • Antimicrobial resistance is depleting the global antibiotic arsenal faster than new drugs are being developed

Impact on Company:

  • Creates opportunity for EXBLIFEP and Cefiderocol products
  • Positions Orchid to address global AMR response through product access, education and responsible use programmes

Management Commentary & Growth Outlook

Strategic Outlook: "The turnaround is complete. The platform is being built. The ambition is clear." - Building a differentiated long-term position in critical antibiotics.

FY Guidance:

  • Plans to launch 5-6 sterile products in US by 2030
  • 7-ACA + Downstream Integration commissioning: FY27
  • Cefiderocol project: Committed - active project

Risks and Opportunities: Not specifically highlighted beyond forward-looking statements disclaimer.

Additional Headings

Antimicrobial Stewardship:

  • Orchid has an active Antimicrobial Stewardship division focused on fighting AMR in India
  • Initiatives include product access, education and responsible use programmes
  • Product basket includes: Orblicef, Ortaro, Orzid-AV, Ceftolozane

Capital Allocation and Growth Priorities:

  • 73% of capital going to 7-ACA + Downstream Integration
  • 20% to Cefiderocol Access Project
  • 5% to FDF Capability & Filings
  • 2% to R&D / Pipeline

Selective Expansion Beyond Cephalosporins:

  • Next 5 Years: 90% Cephalosporin-led
  • Dhanuka's API-FDF assets in non-cephalosporin generics provide a ready physical base for selective expansion